LCZ696 (Valsartan/Sacubitril)--A Possible New Treatment for Hypertension and Heart Failure.
Quick Facts
What This Study Found
LCZ696, a combination of valsartan and sacubitril, demonstrated greater reductions in blood pressure and decreased mortality and morbidity in patients with heart failure with reduced ejection fraction compared to current treatments. It also lowered blood pressure and NT-pro-BNP levels in patients with heart failure with preserved ejection fraction.
Key Numbers
How They Did This
This MiniReview summarizes data from four clinical trials (NCT01193101, NCT00549770, NCT00887588, NCT01035255) assessing LCZ696's effects on hypertension and heart failure patients. The review compares outcomes with those from existing ACE inhibitors and angiotensin receptor blockers.
Why This Research Matters
LCZ696 offers a novel dual-action approach that may improve treatment effectiveness for hypertension and heart failure, conditions with significant health impacts worldwide. Enhancing peptide preservation while blocking harmful pathways could lead to better patient outcomes.
What This Study Doesn't Tell Us
The review is based on early trial data with limited long-term follow-up, and the overall study type and evidence strength are not clearly defined. More extensive and longer-duration studies are needed.
Trust & Context
- Original Title:
- LCZ696 (Valsartan/Sacubitril)--A Possible New Treatment for Hypertension and Heart Failure.
- Published In:
- Basic & clinical pharmacology & toxicology, 118(1), 14-22 (2016)
- Authors:
- Andersen, Mathilde Borring, Simonsen, Ulf, Wehland, Markus, Pietsch, Jessica, Grimm, Daniela
- Database ID:
- RPEP-02865
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-02865APA
Andersen, Mathilde Borring; Simonsen, Ulf; Wehland, Markus; Pietsch, Jessica; Grimm, Daniela. (2016). LCZ696 (Valsartan/Sacubitril)--A Possible New Treatment for Hypertension and Heart Failure.. Basic & clinical pharmacology & toxicology, 118(1), 14-22. https://doi.org/10.1111/bcpt.12453
MLA
Andersen, Mathilde Borring, et al. "LCZ696 (Valsartan/Sacubitril)--A Possible New Treatment for Hypertension and Heart Failure.." Basic & clinical pharmacology & toxicology, 2016. https://doi.org/10.1111/bcpt.12453
RethinkPeptides
RethinkPeptides Research Database. "LCZ696 (Valsartan/Sacubitril)--A Possible New Treatment for ..." RPEP-02865. Retrieved from https://rethinkpeptides.com/research/andersen-2016-lcz696-valsartansacubitrila-possible-new
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.